Outcomes of XXXX treated with adjuvant chemoradiation with @entity2903 and correlation with prognostic factors.

@entity1 @entity2903 @entity2904 @entity463 @entity1349
BACKGROUND: @entity463 ( @entity463 ) @entity1 are underrepresented in major trials for this disease. We aimed to explore the outcome of @entity463 @entity1 treated with concurrent and adjuvant @entity2903 ( @entity2904 ). MATERIALS AND METHODS: 23 @entity1 of @entity463 treated from 2004 to 2010 were included in this retrospective analysis. Adjuvant therapy included conformal radiation 60 gray at 2 gray/fraction daily over 6 weeks with concurrent @entity2904 75 mg/m(2) followed by six cycles of adjuvant @entity2904 150-200 mg/m(2) (day 1-5) every 4 weeks. Kaplan-Meier estimates of @entity1349 ( @entity1349 ) were determined. Univariate analysis with log-rank test was used to determine the impact of prognostic variables on survival. RESULTS: Median age at presentation was 11.5 years (range: 7-19 years) and M:F ratio was 15:8. All @entity1 underwent maximal safe surgical resection; 13 gross total resection and 10 sub-total resection. At a median follow-up of 18 months (range: 2.1-126 months), the estimated median @entity1349 was 41.9 months. The estimated median @entity1349 for @entity1 receiving only concurrent @entity2904 was 8 months while that for @entity1 receiving concurrent and adjuvant @entity2904 was 41.9 months (P = 0.081). Estimated median @entity1349 for @entity1 who did not complete six cycles of adjuvant @entity2904 was 9.5 months versus not reached for those who completed at least six cycles (P = 0.0005). Other prognostic factors did not correlate with survival. CONCLUSIONS: Our study shows the benefit of @entity2904 for @entity463 @entity1 . Both concurrent and adjuvant @entity2904 seem to be important for superior @entity1349 in this group of @entity1 .
